VBI Vaccines Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VBIV Nasdaq 8731 https://www.vbivaccines.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for VBI Vaccines Inc

VBI Vaccines Reports Full Year 2023 Financial Results - Apr 16th, 2024 12:00 pm
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Apr 11th, 2024 8:05 pm
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Apr 9th, 2024 6:45 pm
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma - Apr 3rd, 2024 12:00 pm
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform - Apr 2nd, 2024 12:00 pm
Strategic Licensing Agreements: Brii Bio’s Expansion into Chronic Disease Treatments with VBI Vaccines - Feb 14th, 2024 5:48 pm
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences - Feb 14th, 2024 12:00 pm
VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting - Nov 20th, 2023 1:00 pm
VBI Vaccines Reports Third Quarter 2023 Financial Results - Nov 14th, 2023 9:05 pm
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program - Oct 26th, 2023 12:00 pm
VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern - Sep 27th, 2023 11:30 am
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM - Sep 7th, 2023 12:00 pm
VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B - Sep 6th, 2023 12:00 pm
VBI Vaccines Reports Second Quarter 2023 Financial Results - Aug 14th, 2023 12:00 pm
Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates - Aug 3rd, 2023 10:25 pm
VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common Shares - Jul 24th, 2023 12:00 pm
VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults - Jul 19th, 2023 12:00 pm
7 Biotech Stocks to Sell in July - Jul 13th, 2023 11:00 am
VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering - Jul 6th, 2023 1:00 pm
VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants - Jul 5th, 2023 8:12 pm